TL;DR
- •Ketamine is an NMDA-receptor antagonist; psilocybin is a serotonin 5-HT2A receptor agonist. Both produce psychedelic states and rapid antidepressant effects but through fundamentally different pharmacology.
- •Ketamine is legal in the United States, FDA-approved as an anesthetic, and prescribed off-label for depression by physicians experienced in mood-disorder treatment. Sublingual at-home administration is widely available.
- •Psilocybin is Schedule I federally — illegal to possess or prescribe outside of FDA-authorized clinical trials and Oregon's Measure 109 supervised-use service centers. Australia approved limited psychiatrist-led use in 2023.
- •Goodwin 2022 (NEJM) showed a single 25mg dose of synthetic psilocybin produced a 37% remission rate at week 3 in treatment-resistant depression — encouraging but with regulatory access still years away from broad availability.
- •Carhart-Harris 2021 (NEJM) compared psilocybin to escitalopram head-to-head — comparable depression outcomes, with psilocybin showing some secondary measure advantages.
- •Ketamine produces antidepressant effects within hours; psilocybin produces them after a single 6-8 hour session. Maintenance schedules differ: ketamine typically weekly-to-monthly; psilocybin trials use single doses or every-few-months dosing.
- •For patients seeking a psychedelic-mechanism antidepressant available today, ketamine is the only legal at-home option in the US.
Side by side
Ketamine
Racemic ketamine (NMDA antagonist)
NMDA-receptor antagonist
What it treats
Off-label: treatment-resistant depression, anxiety, PTSD, chronic pain, FDA-approved: anesthesia
Mechanism
Blocks NMDA glutamate receptors, producing an acute glutamate surge, BDNF-mediated synaptic plasticity, and rapid antidepressant effect. Dissociative experience emerges from disrupted thalamocortical signaling and is generally shorter than psilocybin's effect.
Strengths
- •Legal and prescribable today — sublingual at-home option available
- •Rapid onset (hours, not weeks)
- •Decades of safety data in anesthesia and surgical sedation
- •Established maintenance protocols and physician training
Limitations
- •Off-label use for depression — not FDA-approved specifically for psychiatric indications
- •Direct-pay model in at-home settings; in-clinic IV often not insurance-covered
- •Bladder toxicity with frequent high-dose chronic use (recreational pattern, not therapeutic)
- •Dissociation is shorter and less mystical-character than psilocybin for most patients
Psilocybin
Psilocybin (5-HT2A agonist)
Serotonergic psychedelic (Schedule I)
What it treats
Investigational: treatment-resistant depression, end-of-life distress, alcohol/tobacco use disorder, OCD
Mechanism
Active metabolite psilocin is a serotonin 5-HT2A receptor agonist producing 4-6 hour psychedelic experiences with ego dissolution, sensory shifts, and emotional release. Antidepressant effect is hypothesized to come from neuroplasticity changes and the experiential content of the session.
Strengths
- •Strong RCT data — Goodwin 2022 NEJM showed 37% remission at week 3 with a single dose
- •Compared to escitalopram (Carhart-Harris 2021 NEJM) — comparable primary outcome, some secondary advantages
- •Single-session dosing may suffice (vs ongoing ketamine maintenance)
- •Lower potential for chronic-use side effects (single dose at intervals)
Limitations
- •Schedule I federally — only legal access is Oregon supervised-use service centers (state-only legalization) or FDA clinical trials
- •Australia approved psychiatrist-prescribed use in 2023; most patients globally still have no legal access
- •Each session requires 6-8 hours of in-clinic supervision plus integration
- •Cost in available channels (Oregon, Australia) ranges $1,500-$10,000+ per session
- •Not appropriate for patients with personal or family psychotic-spectrum history
Which one for your situation?
If:
You want a psychedelic-mechanism antidepressant available legally today in the US
Verdict:
Ketamine — the only currently-legal option for at-home psychedelic treatment of depression
If:
You live in Oregon and qualify for licensed psilocybin services
Verdict:
Either option valid — but consider cost ($1,500-2,500+ per psilocybin session vs $349/month at Tovani for unlimited ketamine maintenance)
If:
You want a single-session treatment with minimal ongoing maintenance
Verdict:
Psilocybin (where legally available) — single high-dose sessions are the published protocol
If:
Family or personal history of psychotic-spectrum illness
Verdict:
Avoid both classical psychedelics — ketamine is sometimes used with caution, but psilocybin is contraindicated
If:
You want maintenance dosing flexibility based on response
Verdict:
Ketamine — established induction + maintenance protocols with dose flexibility
Where ketamine fits
Tovani provides sublingual ketamine via telehealth in Florida and New Jersey — the legally-available psychedelic-mechanism option in the US for depression, anxiety, and PTSD. For patients drawn to psilocybin's mechanism, ketamine offers a similar rapid-onset paradigm shift without the regulatory and access friction.
Both ketamine and psilocybin produce mood response within hours-to-days of the first session. Ketamine: legal, at-home, $349/month at Tovani. Psilocybin: Schedule I in the US except Oregon supervised-use (~$1,500-2,500+ per session) and FDA trials.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Is psilocybin legal in the United States?
Federally, no — psilocybin remains Schedule I, meaning the DEA classifies it as having no accepted medical use and high abuse potential. The only legal access pathways are (1) FDA-authorized clinical trials, (2) Oregon's Measure 109 licensed psilocybin service centers (in-state use only, $1,500-2,500+ per session), and (3) Colorado's analogous program rolling out. Several other states are considering similar legislation.
Will psilocybin be FDA-approved soon?
COMPASS Pathways and other sponsors have advanced psilocybin programs through Phase 2 with positive results (Goodwin 2022). Phase 3 trials are ongoing. FDA approval is plausible by 2027-2028 if Phase 3 data replicate Phase 2, but timelines for psychedelic drug approval have been unpredictable — see MDMA's FDA rejection in August 2024 despite Phase 3 efficacy data.
Which mechanism is better for depression — NMDA or 5-HT2A?
Both produce rapid antidepressant effects in published trials at comparable response rates. The mechanisms are distinct: ketamine acts through glutamate via NMDA blockade; psilocybin through serotonin via 5-HT2A agonism. Some patients respond to one but not the other — they're not interchangeable. For now, ketamine is the only one accessible to most US patients without joining a clinical trial.
Can I use ketamine while waiting for psilocybin to become legal?
Yes. Many patients drawn to psilocybin's mechanism choose ketamine in the interim — it's legally accessible today, has decades of safety data, and produces a similar rapid-onset antidepressant effect through a different but related pathway. Ketamine and psilocybin aren't direct substitutes for each other, but for depression specifically, both offer mechanism-distinct options compared to SSRIs.
Is the experience similar?
Different. Ketamine produces shorter (60-120 min at therapeutic doses), more dissociative and ego-detached experiences. Psilocybin produces longer (4-6 hours), more visual and emotionally-rich experiences with stronger mystical-experience character. Some patients prefer one over the other based on temperament and goals.
References
- Goodwin GM et al. 2022, New England Journal of Medicine. Single-dose psilocybin RCT in treatment-resistant depression — 37% remission rate at week 3 with 25mg synthetic psilocybin, establishing the modern evidence base for psilocybin-assisted therapy. PMID 36322843
- CarhartHarris RL et al. 2021, New England Journal of Medicine. Trial of Psilocybin versus Escitalopram for Depression — comparable primary outcome with psilocybin showing some secondary measure advantages. PMID 33852780
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo, establishing ketamine's rapid antidepressant effect. PMID 23982301
- Hughes B et al. 2025, Cureus. Comparative review of ketamine and psilocybin as therapeutic options for depression, anxiety, and trauma-related disorders. PMID 40970030